**Name of journal:** *World Journal of Pharmacology*

**Manuscript NO:** 42393

**Manuscript type:** MINIREVIEWS

**Pharmacology and clinical applications of flupirtine: Current and future options**

Lawson K. Pharmacology of flupirtine

Kim Lawson

**Kim Lawson,** Department of Biosciences and Chemistry, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield S1 1WB, United Kingdom

**ORCID number**: Kim Lawson (0000-0002-5458-1897).

**Author contributions:** Lawson K researched the materials for the article and wrote the manuscript.

**Conflict-of-interest** **statement:** There is no conflict of interest associated with the author for the contributions in this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author**: **Kim Lawson, PhD, Senior Lecturer,** Department of Biosciences and Chemistry, Biomolecular Sciences Research Centre, Sheffield Hallam University, City Campus, Howard Street, S1 1WB, United Kingdom. k.lawson@shu.ac.uk

**Telephone:** +44-114-2253057

**Fax:** +44-114-2253066

**Received:** September 21, 2018

**Peer-review started:** September 23, 2018

**First decision:** November 5, 2018

**Revised:** November 17, 2018

**Accepted:** January 5, 2019

**Article in press:**

**Published online:**

**Abstract**

Flupirtine is the first representative in a class of triaminopyridines that exhibits pharmacological properties leading to the suppression of over excitability of neuronal and non-neuronal cells. Consequently, this drug has been used as a centrally acting analgesic in patients with a range of acute and persistent pain conditions without the adverse effects characteristic of opioids and non-steroidal anti-inflammatory drug and is well tolerated. The pharmacological profile exhibited involves actions on several cellular targets, including Kv7 channels, G-protein-regulated inwardly rectifying K channels andγ-aminobutyric acid type A receptors, but also there is evidence of additional as yet unidentified mechanisms of action involved in the effects of flupirtine. Flupirtine has exhibited effects in a range of cells and tissues related to the locations of these targets. In additional to analgesia, flupirtine has demonstrated pharmacological properties consistent with use as an anticonvulsant, a neuroprotectant, skeletal and smooth muscle relaxant, in treatment of auditory and visual disorders, and treatment of memory and cognitive impairment. Flupirtine is providing important information and clues regarding novel mechanistic approaches to the treatment of a range of clinical conditions involving hyper-excitability of cells. Identification of molecules exhibiting specificity for the pharmacological targets (*e.g.,* Kv7 isoforms) involved in the actions of flupirtine will provide further insight into clinical applications. Whether the broad-spectrum pharmacology of flupirtine or target-specific actions is preferential to gain benefit, especially in complex clinical conditions, requires further investigation. This review will consider recent advancement in understanding of the pharmacological profile and related clinical applications of flupirtine.

**Key words:** Flupirtine; Kv7 channels; GABAA receptors; Analgesia; Seizures; Neuroprotection; Myotonia; Memory; Tinnitus

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Flupirtine exhibits pharmacological properties due to actions on Kv7 channels, G-protein-regulated inwardly rectifying K channels and γ-aminobutyric acid type A receptors leading to the suppression of over excitability of neuronal and non-neuronal cells. Consequently flupirtine has demonstrated efficacy consistent with use as an analgesic, an anticonvulsant, a neuroprotectant, skeletal and smooth muscle relaxant, in treatment of auditory and visual disorders, and treatment of memory and cognitive impairment. Flupirtine is providing important information and clues regarding novel mechanistic approaches to the treatment of a range of clinical conditions involving hyper-excitability of cells.

Lawson K. Pharmacology and clinical applications of flupirtine: Current and future options. *World J Pharmacol* 2019; In press

**INTRODUCTION**

Flupirtine is the first representative in a class of triaminopyridines that exhibits pharmacological properties leading to the suppression of neuronal over excitability. Consequently, this molecule has demonstrated to be beneficial in treating patients with a range of pain conditions[1-4]. Flupirtine relative to other analgesics on the market exhibits unique chemical structure and modes of action that contribute to a preferable pharmacological profile. It does not possess the adverse effects characteristic of opioids and non-steroidal anti-inflammatory drug and is well tolerated.

Flupirtine has been classified as a selective neuronal potassium channel opener due to action on voltage-gated K channels belonging to the Kv7 subfamily (with selectivity for the Kv7.2-Kv7.5 isoforms) and G-protein-regulated inwardly rectifying K (GIRK) channels[5,6]. Channel activation by flupirtine will lead to hyperpolarization of the membrane potential and attenuates the generation of action potentials, thus offering a novel therapeutic approach for diseases associated with cellular hyperexcitability[5].

Flupirtine has been the subject of a few good reviews describing it’s history and clinical profile as a treatment of pain[1-4]. In addition, flupirtine has been used as a pharmacological tool to gain greater understanding of Kv7 channels as a therapeutic target[7-9]. The aim of this review is to consider the advancement in recent understanding of the pharmacological profile and related clinical applications of flupirtine. MEDLINE database, Web of Science and Google Scholar were used to identify relevant studies and publications up to July 2018 using the term “flupirtine”. Flupirtine exhibits an interesting pharmacological profile that offers clues of potential targets that merit investigation as novel therapeutic approaches to a range of clinical conditions.

**ANALGESIA**

Pain relieving activity in various animal models and humans has been demonstrated with flupirtine a non-opioid analgesic without anti-inflammatory or antipyretic properties[1-3]. Effective analgesia by flupirtine has been demonstrated in a range of persistent pain conditions such as musculoskeletal pain, postoperative pain, migraine and neuralgia[2,3,10,11]. These effects of flupirtine are associated with restoration of normal sensitivity of over-excitable nociceptive pathways and inhibition of the stimulation of nociceptive neurons by factors such as inflammatory mediators (*e.g.,* bradykinin)[12-15]. In small fibre neuropathy the efficacy of flupirtine was reported to be sufficient to lead to the discontinuation of first-line drug treatments, such as gabapentin and amitriptyline, which are often associated with adverse effects or unsatisfactory pain relief[16].

Flupirtine stabilizes the membrane resting potential by activating KCNQ (Kv7) potassium channels generating a neuronal hyperpolarizing current (M-current)[5]. Activation of potassium channels will lead to an indirect N-methyl-D-aspartate (NMDA) receptor antagonism, thus reducing hyperexcitation of nociceptive neurons. In addition, Mg2+ block on NMDA receptors is maintained by an oxidizing action of flupirtine at the redox site of the receptor consistent with an indirect inhibition[17]. There is however no interaction with the binding site of the NMDA receptor[6].

Kv7 channels encompass five members of which Kv7.2–Kv7.5 are expressed and distributed throughout peripheral nerves and the CNS, and co-assemble to form either homo- or hetero-tetramers[18,19]. Agonist action at (Gq/11) G protein-coupled receptors, such as acetylcholine at muscarinic receptors, can inhibit channel activity. Kv7 channels are expressed in neurons forming the nociceptive pathways, such as central terminals of primary afferents and dorsal horn neurons within the spinal cord[20]. Long-term downregulation of Kv7 subunits following neuropathic injury, whether due to trauma or inflammation, has been proposed to contribute to hyperexcitability of sensory fibres[21]. Increased levels of repressor element1-silencing transcription factor leading to reduced density of Kv7.2, Kv7.3 and Kv7.5 is a delayed feature of neuropathic injury with probable involvement in the maintenance rather than the initiation of pain[22]. The decreased channel density was functionally compensated by the activation of residual Kv7 channels by flupirtine resetting neurons to a low-excitable state and suppressing pain[21]. Flupirtine exhibits efficacy on all four subunits, Kv7.2, Kv7.3, Kv7.4 and Kv7.5, with an apparent preference for Kv7.3. Interestingly, flupirtine appeared to evoke an effect specifically in injured neurons and not uninjured fibres[21]. Associated with the analgesic activity of flupirtine is the ability of inhibiting the release of neurotransmitters, such as calcitonin-gene related peptide, from the brainstem following the opening of Kv7 channels[23].

Flupirtine has been found to act simultaneously on Kv7 channels and γ-aminobutyric acid type A (GABAA) receptors which are both involved in the control of nociception[24]. Thus, the combined stimulatory action in pain neural circuits may contribute to the analgesic activity of flupirtine. The subunit composition of the GABA receptor defines specific pharmacological characteristics such that benzodiazepines modulate 2-subunit containing receptors, whereas -subunits are highly sensitive towards neurosteroids[25,26]. Preferential action by flupirtine at -subunit containing GABAA receptors over -containing GABAA receptors has been demonstrated[27]. The presence of 4 and 6 subunits renders -subunit containing GABAA receptors insensitive to benzodiazepines[28,29]. Thus, the pharmacological properties of flupirtine due to interaction with GABA receptors will have a profile that differs from that exhibited by benzodiazepines. Although the induction of addictive behaviours in certain drugs is associated with agonism at GABAA receptors, such properties of flupirtine have had limited anecdotal reporting[30,31].

Synergistic or additive effects with other analgesics have been suggested to be likely for molecules that inhibit the NMDA receptor[32]. Flupirtine and opioids have been reported to exhibit synergistic analgesic interactions[32,33]. Synergistic interactions have also been observed with flupirtine and the atypical opioids, tramadol and tapentadol, which exhibit the dual mechanisms of action of -opioid receptor agonism and inhibition of noradrenaline reuptake[33,34]. Such co-administration will offer benefits such as enhanced analgesic efficacy and prolonged analgesic duration, relative to the minimization of adverse effects and reduction in opioid tolerance.

**ANTICONVULSANT**

Disruption of the excitatory-inhibitory balance in brain neural networks leading to synchronous activation and recurrent seizures characterises epilepsy. Consistent with its ability to suppress neuronal hyperexcitability flupirtine has demonstrated anticonvulsant activity in the Antiepileptic Drug Development program[7].

Studies have demonstrated flupirtine to be very effective against neonatal seizures induced, for example, by hypoxia/ischaemic injury or chemoconvulsants, with efficacy preferable to current anticonvulsant therapies, such as phenobarbital and diazepam[35-37]. Pretreatment with flupirtine prevented development of neonatal electroclinical seizures, whilst administration after the generation of a seizure prevented subsequent seizures and thereby reduced overall seizure burden. In the immature brain compared to that of an adult the GABAergic inhibitory system is underdeveloped and has fewer GABAA receptors, different GABAA receptor subunit composition (*e.g.*, low levels of delta subunits) and lower GABA-mediated currents[38,39]. A decreased efficacy of drugs that target GABAA receptors such as phenobarbital against neonatal seizures is consistent with the brain underdevelopment[38,39]. As described previously, flupirtine evokes stabilization of neuronal hyperexcitability due to activation of Kv7 and GIRK channel activity, and potentiation of GABA responses of the -subunit containing GABAA receptor[24,27]. Although the mechanism responsible for the anti-neonatal seizure activity of flupirtine is unknown, involvement of Kv7 activation is the more likely explanation of providing greater efficacy than and thereby advantage over GABA receptor modulating drugs.

In neonatal rats, flupirtine induced a burst suppression-like electroencephalography (EEG) pattern[36]. Burst suppression is when high voltage activity alternating with periods of no activity in the brain characterize the EEG pattern. Refractory status epilepticus can be terminated by the induction of the burst suppression pattern by midazolam, and as observed with flupirtine[40]. In rat models of established status epilepticus initial data indicated that the combination of flupirtine and diazepam terminated seizures preferentially to either drug alone, however efficacy of flupirtine alone appeared dependent on the animal model[41]. Thus, the potential benefit in the clinic available from treatment with flupirtine may be dependent on the underlying aetiology of established status epilepticus.

Febrile seizures are the most common convulsive events in infants and young children where recurrence may be a risk factor for greater likelihood of later epilepsy[42]. Repetitive febrile seizures (RFS) have been associated with impaired hippocampus-dependent long-term memory[43]. Current anti-convulsant drugs, including diazepam, phenobarbital and sodium valproate, although have proven effective at reducing seizure recurrence are limited due to adverse effects[44]. In a rat model of RFS, flupirtine suppressed seizures and reduced risk of further seizures[45]. Further, flupirtine was effective against RFS-induced learning and memory impairment and reduced RFS-induced neuronal degeneration. In this RFS model improvement due to flupirtine treatment was greater than that observed with current treatment for recurrent febrile seizures, phenobarbital[45]. Activation of Kv7 channels is the probable property responsible for the efficacy of flupirtine for the treatment of RFS. Consistent with this conclusion is the observation that the expression level of Kv7.2 subunits is low in neonatal neurons and after the first post-natal week increases, which inversely correlates with the incidence of febrile seizures decreasing with age[46].

**NEUROPROTECTION**

Neuroprotective activity has been exhibited by flupirtine in a variety of neurodegenerative disease models and clinical trials with suggestion of utility as a therapeutic approach in conditions such as Alzheimer’s disease, Parkinson’s disease, Creutzfeldt-Jakob disease, prion disease, age-related macular degeneration and Batten disease[2-4,47,48]. Indirect antagonism of the NMDA receptor and thereby glutamate-induced intracellular Ca2+ increase, upregulation of the antiapoptotic protein B-cell lymphoma 2 (Bcl-2) and antioxidant activity via increased glutathione levels and reduced reactive oxygen species levels have all been suggested to be involved in the neuroprotective properties of flupirtine[2-4].

In experimental models of stroke flupirtine evoked neuroprotection when administered before or up to 9 hours post induction of cerebral ischaemia[49-51]. An important signalling pathway contributing to post-ischaemic proteolysis and cell death is an NMDA-induced intracellular calcium increase leading to activation of calpain[52]. Calpain is involved in the degradation of signal-transducer-and-activator-of-transcription-6 (STAT6) which in healthy brains inhibits c-Jun-N-terminal kinases (JNK) and nuclear factor-κB (NF-κB) signalling pathways which are critical to the progression of ischaemic brain injury[51]. As a consequence of indirect NMDA receptor antagonism flupirtine at clinically relevant concentrations reduces the calcium dependent calpain activation and restores the STAT6-induced inhibition of JNK and NF-κB pathways and proteasomal activity[51]. Thus, following flupirtine treatment infarct volumes were reduced, the blood brain barrier integrity stabilized and the inflammatory response and oxidative stress within the ischaemic lesion site reduced.

Chronic stress increases the susceptibility of neurons in the brain to injury with the induction of apoptosis particularly within the hippocampus, which has been proposed to contribute to impaired brain function and stress-related cognitive deficits[53]. In a chronic stress model, flupirtine prevented impairment of spatial learning and memory, alleviated neuronal apoptosis and the reduction of dendritic spine density in the hippocampus[54]. Flupirtine reversed the chronic stress-induced increased expression of the pro-apoptoic regulator Bax, inactivation of the protein kinase B (Akt)/glycogen synthase kinase-3 pathway, which regulates learning and memory, synaptic plasticity and cell survival, and reduction in the extracellular signal-regulating kinase 1/2 signalling pathway, which plays a role in cognitive processing[54]. The role of Kv7 channels and/or GABAA receptors in the effects of flupirtine in chronic stress however need clarification. Interestingly, flupirtine has also been shown to prevent acute stress-induced impairment of spatial memory retrieval and hippocampal long-term potentiation[55]. Activation of Kv7 channels by flupirtine was suggested to be responsible for the reduction in the acute stress-induced impaired memory formation.

Bcl-2 protein complexes with beclin 1 leading to an inhibition of autophagy, thus raised expression of Bcl-2 will influence proteostasis and cell death in neurodegenerative diseases[56]. The Prp106-126 fragment of the prion protein, which is toxic to cortical neurons and involved in the development of prion diseases, reduced levels of the anti-apoptotic proto-oncogene Bcl-2 and of glutathione[57]. Flupirtine blocked the decrease in glutathione and induced the expression of Bcl-2 reducing cell toxicity due to prion protein exposure[57]. Consistent with these findings the cognitive decline in patients with Creutzfeldt-Jakob disease, in a randomized double-blind clinical trial, was decreased following treatment with flupirtine although there were no significant effects on survival[58].

**SKELETAL MUSCLE RELAXANT**

Flupirtine evokes a reduction in skeletal muscle rigidity and akinesia by the suppression of spinal mono- and polysynaptic reflexes mediated by NMDA receptors[59,60]. The monosynaptic Hoffmann reflex (H-reflex), which does not involve NMDA receptors, was not influenced by flupirtine[59]. These properties of flupirtine are compatible as a therapeutic approach to the treatment of muscle rigidity, spasticity and related musculoskeletal conditions.

The pharmacological properties of flupirtine have also been identified useful in the treatment of myotonia[61,62]. Myotonia and myotonic membrane hyperexcitability induced by anthracene-9-carboxylic acid in murine skeletal muscle was reduced by flupirtine following the activation of Kv7 channels[61]. All KNCQ isoforms are expressed in murine myoblasts with Kv7.2 and Kv7.3 localized at the level of intracellular striations and Kv7.4 subunits restricted to the sarcolemmal membrane[63]. Peripheral nerve hyperexcitability associated with neuromyotonia or myokymia is a consequence of inherited mutations in the human KCNA1 gene, which encode juxtaparanodal Kv1.1 channels, or acquired abnormal autoantibodies targeting Kv1 channel subunits[64,65]. A synergy between Kv1 and Kv7 channels in regulating neuronal excitability has been observed and activation of Kv7 channels with flupirtine can reverse the axon hyperexcitability mediated by Kv1.1 channel deficiency[62]. Thus, flupirtine could be a novel therapeutic approach to Kv1-related conditions involving peripheral nerve hyperexcitability.

**SMOOTH MUSCLE RELAXATION**

Kv7 channels have been identified as important regulators of contractility of vascular, gastrointestinal, urogenital, and tracheobronchial smooth muscle[66]. In smooth muscle cells, Kv7 channels are basally active contributing to stabilizing the resting membrane potential at lower levels and counter depolarizing stimuli, thus reducing cell excitability and contractility. Kv7 channels contribute to the resting membrane potential in smooth muscle cells due to their slow inactivation and low voltage threshold for activation[66].

It is well established that resting membrane potential and contractility in various blood vessels is regulated by Kv7 channels[67]. Expression of KCNQ1, KCNQ4 and KCNQ5 has been reported in a diversity of human, rat and mouse arteries and veins, with KCNQ2 and KCNQ3 expression observed less frequently[66-68]. Many pathological conditions, such as pulmonary hypertension and hyperglycaemia, have been associated with altered expression and function of Kv channels in coronary artery myocytes[69-71]. In addition, reduced expression of Kv7.4 channels have been observed in coronary, renal, and mesenteric arteries of hypertensive rats[72]. Flupirtine evoked concentration-dependent relaxation of rat left and right coronary arteries, with an increase in potassium channel current amplitude and membrane hyperpolarization in myocytes from left coronary arteries but not from right coronary arteries[73]. The differential effects of flupirtine on coronary arteries may be associated with the expression of Kv7.5 being significantly higher in left than in right coronary arteries, whilst Kv7.4 expression was similar. The flupirtine-induced relaxation of porcine left circumflex coronary artery was reduced following endothelial denudation[68]. The flupirtine-induced relaxant response in intact, but not that in artery denuded of endothelium, was inhibited by the non-selective Kv7 channel antagonist linopirdine consistent with the activation of Kv7 channels by flupirtine. In contrast, structurally different Kv7 channels activators (S)-1, retigabine, BMS-254352 and ML213 evoked linopirdine-sensitive relaxations of precontracted porcine and rat coronary arteries that were not affected by removal of the endothelium[74,75]. In porcine left coronary arteries immunohistochemical staining for Kv7.4 was prominent in the intimal (endothelial) layer, but less in the medial (smooth muscle) layer[68]. Strong Kv7.4 immunostaining however was observed in the medial and intimal layers of porcine right coronary artery, and Kv7.5 immunostaining was strong only in the intimal layer with much weaker intensity in the intimal layer[75]. The differential endothelial-dependent effects may be due to the distribution and density of channel subtype expression combined with potential subtype selectivity profile of flupirtine relative to other Kv7 channel activators. Thus, the vasorelaxant response to flupirtine in coronary arteries appears to involve endothelium based Kv7 channels and an as yet unidentified mechanism in the smooth muscle cells.

Flupirtine evoked pulmonary vasodilation in lungs from hypoxic rats but not from normoxic rats[76]. Consequently, raised pulmonary vascular resistance due to hypoxia could be prevented and reversed by flupirtine[76,77]. Hypoxia leads to the downregulation of Kv7.4, but not Kv7.1 nor Kv7.5, channels and smooth muscle cell depolarisation. Although the molecular target responsible for the actions of flupirtine have not been identified, activation of the residual Kv7.4 channels, of Kv7.5 channels or a combination of Kv7.4/7.5 needs further evaluation. The Kv7 activation exhibited by flupirtine would be a potential treatment approach for pulmonary hypertension.

Activation of Kv7 channels in bladder smooth muscle cells will dampen electrical activity and regulate excitability. In guinea pig bladder detrusor smooth muscle flupirtine hyperpolarized the cell membrane with a simultaneous cessation of spontaneous transient depolarizing electrical activity and suppression of myogenic spontaneous contractions[78]. Takagi and Hashitani (2016) observed that flupirtine abolished spontaneous action potential discharge in guinea pig detrusor smooth muscle cells without hyperpolarization with the suggestion that only modest opening of Kv7 channels is required[79]. Interestingly Kv7 channels were suggested to only be partial responsible for the flupirtine-induced reduction of the amplitude of spontaneous action potentials associated with spontaneous activity of guinea pig muscularis mucosae[80]. Flupirtine, following Kv7 channel activation, evoked relaxations of the human detrusor muscle, of which overactivity is frequently present in overactive bladder syndrome[81]. As with the guinea pig smooth muscle cells, all five KCNQ genes which encode Kv7.1-7.5 channels are expressed in the human detrusor with the Kv7.4 channel subunit showing the highest expression level[81,82]. Thus, selective Kv7.4 channel activators would be preferential novel therapeutic treatments of urinary bladder overactivity conditions. Human overactive bladder or detrusor overactivity in animal models are characterized by increases in spontaneous activity, thus ideal treatment strategy of overactive bladder would be modulation of the spontaneous excitability[83].

All KCNQ isoforms, except KCNQ5, are expressed in human myometrial smooth muscle tissue with a predominance of KCNQ4 and KCNQ1[84]. Thus, the expression profile of KCNQ genes in the uterus resembles other smooth muscles. Although all KCNQ isoforms were expressed in myometrium from pregnant mice in early and late gestation, KCNQ1, KCNQ2, KCNQ4 and KNCQ5 all up-regulated in late pregnancy[83]. Flupirtine suppressed myometrial contractile activity, with a partial effect in early gestation animals and a profound action in late gestation mice[84]. Although no teratogenic effects of flupirtine are known or have been reported in animal studies, the potential risk for humans is unknown[85]. Thus, Kv7 channel activation by flupirtine could be a novel approach for tocolysis for use in human preterm labour.

Flupirtine has exhibited relaxing properties of gastrointestinal smooth muscle such as rat stomach and human taenia coli[86,87]. In gastrointestinal tract tissues from animals and humans Kv7.4 and Kv7.5 isoforms had the highest expression levels, with the former being the predominant channel[88]. Thus, this property of flupirtine would be relevant for the treatment of gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome[88].

Flupirtine has been shown to enhance Kv7 currents in guinea pig airways smooth muscle cells and evoke relaxation of precontracted human airways thereby indicating utility as an effective bronchodilator[89]. In human airways smooth muscle cells expression of KCNQ1, KCNQ4 and KCNQ5 has been reported, whilst KCNQ2 and KCNQ3 were undetectable[90]. In mouse and rat tracheal smooth muscle cells where the expression of KCNQ subtypes reflects that observed in human tissue, flupirtine evoked Kv7 channel dependent hyperpolarization and relaxation[91]. Interestingly, KCNQ2 was the most abundant isoform detected in guinea pig airways smooth muscle cells, suggesting this species may not predict clinical efficacy of flupirtine and similar drugs[89].

**Auditory and Ocular properties**

Reduction in Kv7.2 and Kv7.3 channel activity leading to hyperactivity in the dorsal cochlear nucleus (an auditory brainstem nucleus) has been associated with the initiation of the auditory disorder tinnitus[92]. Flupirtine inhibited the spontaneous activity in mouse auditory cortical networks which was suggested to involve Kv7 channel activation[93]. These findings are consistent with the pharmacological properties of flupirtine being relevant to the treatment of tinnitus.

Retinal ganglion cell hyperactivity is associated with photoreceptor dystrophic disorders and blindness. Flupirtine decreased spontaneous firing and sensitivity to optogenetic stimulation in mice retinal ganglion cells sensitive to channel rhodopsin2 stimulation[94-96]. Thus, an increase in activity or expression of Kv7 potassium channels, the specific subtypes as yet have not been identified, in retinal amacrine cells would result in decreased spontaneous activity and could be a therapeutic approach to visual disorders.

**ADVERSE EFFECTS AND TOLERABILITY**

Most common adverse effects associated with flupirtine treatment (i.e. dizziness, drowsiness, nausea, dry mouth, heartburn, fatigue, headache) which occurred within 6 mo of treatment were reported to be mild and transient[2-4]. Consequently flupirtine has been viewed as well tolerated as reflected by regular use since it was first approved in the 1980s.

Long-term flupirtine treatment has been associated with liver injury with rare cases of liver failure and fatality[97,98]. Complex hepatic metabolism of flupirtine involving N-glucuronidation, hydrolysis and N-acetylation leads to the formation of an active metabolite D13223[99,100]. Flupirtine is hydrolysed by carboxylesterase and N-acetyltransferase 2 (NAT2) appears responsible for the acetylation of the hydrolysed metabolite of flupirtine[100]. Reactive quinone diimines, which conjugate with glutathione, however appear to also be formed from the hydrolysed metabolite through non-enzymatic conversion. The quinone diimine intermediates of flupirtine, like the quinone imines intermediates formed with paracetamol and diclofenac, are candidates for the cellular toxicity[100-102]. Thus, acetylation by NAT2 or conjugation by glutathione detoxify by preventing the build-up of quinone diimines[100]. The genetic polymorphisms of NAT2 which show a large inter-individual variability due to genetic polymorphisms and thereby variation in acetylation efficiency could be critical for flupirtine-induced liver injury[100,103]. Humans that exhibit high carboxylesterase activity with slow NAT2 acetylation and have low hepatic glutathione stores appear to be highly susceptible to flupirtine-induced liver injury[100]. Other risk factors have been proposed such as single nucleotide polymorphisms of human leukocyte antigen and myeloperoxidase[99,104].

The flupirtine related hepatotoxicity leads to extensive perivenular (zone 3) necrosis with infiltration of ceroid-pigment containing macrophages and lymphocytes[97]. Vulnerability of zone 3 hepatocytes to necrosis appears to be related to stores of glutathione, which detoxifies the reactive quinone diimines, being depleted with a reduced ability to be replenished[97]. N-acetylcysteine, essential for the replenishment of depleted glutathione stores, in combination with prednisolone treatment in patients with flupirtine-induced liver injury has been shown to improve serum biochemistries including alanine aminotransferase and aspartate aminotransferase[105].

The potential of flupirtine-induced liver injury, although rare, led to the European Medicines Agency's Pharmacovigilance Risk assessment committee issuing risk minimization measures (RMM)[106-108]. As a consequence of limited adherence to the RMM by prescribers flupirtine containing medications were withdrawn from the European market[106].

**Conclusion**

Flupirtine has been used extensively for more than 30 years in the management of pain[2-4]. Effectiveness has been demonstrated in a range of neuronal and non-neuronal biological systems consistent with therapeutic potential as treatment of a diversity of clinical conditions (Table 1). The pharmacological profile exhibited involves actions on several cellular targets, including Kv7 channels, GIRK channels and GABAA receptors. Although many effects can be accounted for as the result of activation of Kv7 channels, there is suggestion that yet unidentified mechanisms of action may also be involved in the effects of flupirtine.

Flupirtine is providing important information regarding novel mechanistic approaches to the treatment of different clinical conditions. Molecules exhibiting specificity for the pharmacological targets (*e.g.,* Kv7 isoforms) involved in the actions of flupirtine will provide further insight into their clinical potential. Whether the broad-spectrum pharmacology of flupirtine or target-specific actions is preferential to gain benefit, especially in complex clinical conditions, requires further investigation.

Whilst the rare hepatotoxicity associated with flupirtine may limit its use, at risk subjects can be identified by hepatic enzyme screening and risk can be limited by glutathione supplement to replenish stores. Investigation of the oxidative metabolites of flupirtine have been reported to contribute to the activation of Kv7.2/Kv7.3 channels mechanism of action, but not to hepatotoxicity[109]. Thus, the analgesic activity, at least, and cytotoxicity in hepatocytes appear separable in this class of drugs.

In conclusion, flupirtine, in addition to use as an analgesic, shows potential for repurposing as a novel approach to clinical conditions such as tinnitus, visual impairment, memory impairment, requiring neuroprotection or requiring smooth muscle relaxation. Identifying new uses for existing drugs or repurposing by passes time and cost of drug development. Finally, the pharmacology of flupirtine can also stimulate the identification of next generation related drugs exhibiting target specific actions.

**References**

1 **Friedel HA**, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. *Drugs* 1993; **45**: 548-569 [PMID: 7684675 DOI: 10.2165/00003495-199345040-00007]

2 **Devulder J**. Flupirtine in pain management: pharmacological properties and clinical use. *CNS Drugs* 2010; **24**: 867-881 [PMID: 20839897 DOI: 10.2165/11536230-000000000-00000]

3 **Szelenyi I**. Flupirtine, a re-discovered drug, revisited. *Inflamm Res* 2013; **62**: 251-258 [PMID: 23322112 DOI: 10.1007/s00011-013-0592-5]

4 **Harish S**, Bhuvana K, Bengalorkar GM, Kumar T. Flupirtine: Clinical pharmacology. *J Anaesthesiol Clin Pharmacol* 2012; **28**: 172-177 [PMID: 22557738 DOI: 10.4103/0970-9185.94833]

5 **Kornhuber J**, Bleich S, Wiltfang J, Maler M, Parsons CG. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication. *J Neural Transm (Vienna)* 1999; **106**: 857-867 [PMID: 10599868 DOI: 10.1007/s007020050206]

6 **Jakob R**, Krieglstein J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurones. *Br J Pharmacol* 1997; **122**: 1333-1338 [PMID: 9421279 DOI: 10.1038/sj.bjp.0701519]

7 **Miceli F**, Soldovieri MV, Martire M, Taglialatela M. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. *Curr Opin Pharmacol* 2008; **8**: 65-74 [PMID: 18061539 DOI: 10.1016/j.coph.2007.10.003]

8 **Brown DA**, Passmore GM. Neural KCNQ (Kv7) channels. *Br J Pharmacol* 2009; **156**: 1185-1195 [PMID: 19298256 DOI: 10.1111/j.1476-5381.2009.00111.x]

9 **Gribkoff VK**. The therapeutic potential of neuronal KCNQ channel modulators. *Expert Opin Ther Targets* 2003; **7**: 737-748 [PMID: 14640909 DOI: 10.1517/14728222.7.6.737]

10 **Mastronardi P**, D'Onofrio M, Scanni E, Pinto M, Frontespezi S, Ceccarelli MG, Bianchi F, Mazzarella B. Analgesic activity of flupirtine maleate: a controlled double-blind study with diclofenac sodium in orthopaedics. *J Int Med Res* 1988; **16**: 338-348 [PMID: 3058538 DOI: 10.1177/030006058801600503]

11 **Chinnaiyan S**, Sarala N, Arun HS. A comparative study of efficacy and safety of flupirtine versus piroxicam in postoperative pain in patients undergoing lower limb surgery. *J Pain Res* 2017; **10**: 2471-2477 [PMID: 29081669 DOI: 10.2147/JPR.S144647]

12 **Busserolles J**, Tsantoulas C, Eschalier A, López García JA. Potassium channels in neuropathic pain: advances, challenges, and emerging ideas. *Pain* 2016; **157** Suppl 1: S7-14 [PMID: 26785158 DOI: 10.1097/j.pain.0000000000000368]

13 **Passmore GM**, Selyanko AA, Mistry M, Al-Qatari M, Marsh SJ, Matthews EA, Dickenson AH, Brown TA, Burbidge SA, Main M, Brown DA. KCNQ/M currents in sensory neurons: significance for pain therapy. *J Neurosci* 2003; **23**: 7227-7236 [PMID: 12904483 DOI: 10.1523/JNEUROSCI.23-18-07227.2003]

14 **Du X**, Gao H, Jaffe D, Zhang H, Gamper N. M-type K+ channels in peripheral nociceptive pathways. *Br J Pharmacol* 2018; **175**: 2158-2172 [PMID: 28800673 DOI: 10.1111/bph.13978]

15 **Linley JE**, Pettinger L, Huang D, Gamper N. M channel enhancers and physiological M channel block. *J Physiol* 2012; **590**: 793-807 [PMID: 22155935 DOI: 10.1113/jphysiol.2011.223404]

16 **Mishra S**, Choudhary P, Joshi S, Bhatnagar S. Successful use of flupirtine in refractory neuropathic pain due to small fiber neuropathy. *Am J Hosp Palliat Care* 2013; **30**: 91-93 [PMID: 22495792 DOI: 10.1177/1049909112441387]

17 **Osborne NN**, Cazevieille C, Wood JP, Nash MS, Pergande G, Block F, Kosinski C, Schwarz M. Flupirtine, a nonopioid centrally acting analgesic, acts as an NMDA antagonist. *Gen Pharmacol* 1998; **30**: 255-263 [PMID: 9510072]

18 **Wang HS**, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, Dixon JE, McKinnon D. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. *Science* 1998; **282**: 1890-1893 [PMID: 9836639 DOI: 10.1126/science.282.5395.1890]

19 **Hernandez CC**, Zaika O, Tolstykh GP, Shapiro MS. Regulation of neural KCNQ channels: signalling pathways, structural motifs and functional implications. *J Physiol* 2008; **586**: 1811-1821 [PMID: 18238808 DOI: 10.1113/jphysiol.2007.148304]

20 **Rivera-Arconada I**, Roza C, Lopez-Garcia JA. Enhancing m currents: a way out for neuropathic pain? *Front Mol Neurosci* 2009; **2**: 10 [PMID: 19680469 DOI: 10.3389/neuro.02.010.2009]

21 **Rose K**, Ooi L, Dalle C, Robertson B, Wood IC, Gamper N. Transcriptional repression of the M channel subunit Kv7.2 in chronic nerve injury. *Pain* 2011; **152**: 742-754 [PMID: 21345591 DOI: 10.1016/j.pain.2010.12.028]

22 **Mucha M**, Ooi L, Linley JE, Mordaka P, Dalle C, Robertson B, Gamper N, Wood IC. Transcriptional control of KCNQ channel genes and the regulation of neuronal excitability. *J Neurosci* 2010; **30**: 13235-13245 [PMID: 20926649 DOI: 10.1523/JNEUROSCI.1981-10.2010]

23 **Tringali G**, Greco MC, Capuano A, Guerriero G, Currò D, Navarra P. Flupirtine inhibits calcitonin-gene related peptide release from rat brainstem in vitro. *Neurosci Lett* 2012; **506**: 332-335 [PMID: 22155095 DOI: 10.1016/j.neulet.2011.11.039.]

24 **Klinger F**, Geier P, Dorostkar MM, Chandaka GK, Yousuf A, Salzer I, Kubista H, Boehm S. Concomitant facilitation of GABAA receptors and KV7 channels by the non-opioid analgesic flupirtine. *Br J Pharmacol* 2012; **166**: 1631-1642 [PMID: 22188423 DOI: 10.1111/j.1476-5381.2011.01821.x]

25 **Farrant M**, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. *Nat Rev Neurosci* 2005; **6**: 215-229 [PMID: 15738957 DOI: 10.1038/nrn1625]

26 **Brickley SG**, Mody I. Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. *Neuron* 2012; **73**: 23-34 [PMID: 22243744 DOI: 10.1016/j.neuron.2011.12.012]

27 **Klinger F**, Bajric M, Salzer I, Dorostkar MM, Khan D, Pollak DD, Kubista H, Boehm S, Koenig X. δ Subunit-containing GABAA receptors are preferred targets for the centrally acting analgesic flupirtine. *Br J Pharmacol* 2015; **172**: 4946-4958 [PMID: 26211808 DOI: 10.1111/bph.13262]

28 **Sieghart W**, Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. *Curr Top Med Chem* 2002; **2**: 795-816 [PMID: 12171572]

29 **Tan KR**, Rudolph U, Lüscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. *Trends Neurosci* 2011; **34**: 188-197 [PMID: 21353710 DOI: 10.1016/j.tins.2011.01.004]

30 **Gahr M**, Freudenmann RW, Kölle MA, Schönfeldt-Lecuona C. Dependence on flupirtine. *J Clin Pharmacol* 2013; **53**: 1003-1004 [PMID: 23846806 DOI: 10.1002/jcph.129]

31 **Stoessel C**, Heberlein A, Hillemacher T, Bleich S, Kornhuber J. Positive reinforcing effects of flupirtine--two case reports. *Prog Neuropsychopharmacol Biol Psychiatry* 2010; **34**: 1120-1121 [PMID: 20362025 DOI: 10.1016/j.pnpbp.2010.03.031]

32 **Kolosov A**, Goodchild CS, Williams ED, Cooke I. Flupirtine enhances the anti-hyperalgesic effects of morphine in a rat model of prostate bone metastasis. *Pain Med* 2012; **13**: 1444-1456 [PMID: 23078152 DOI: 10.1111/j.1526-4637.2012.01502.x]

33 **Capuano A**, De Corato A, Treglia M, Tringali G, Navarra P. Flupirtine antinociception in the rat orofacial formalin test: an analysis of combination therapies with morphine and tramadol. *Pharmacol Biochem Behav* 2011; **97**: 544-550 [PMID: 21073890 DOI: 10.1016/j.pbb.2010.11.002]

34 **Lee H**, De Vito V, Giorgi M, Yun H. Synergistic interaction between tapentadol and flupirtine in the rat orafacial formalin test. *Eur J Pharmacol* 2015; **762**: 350-356 [PMID: 26048311 DOI: 10.1016/j.ejphar.2015.05.064]

35 **Raol YH**, Lapides DA, Keating JG, Brooks-Kayal AR, Cooper EC. A KCNQ channel opener for experimental neonatal seizures and status epilepticus. *Ann Neurol* 2009; **65**: 326-336 [PMID: 19334075 DOI: 10.1002/ana.21593]

36 **Sampath D**, Shmueli D, White AM, Raol YH. Flupirtine effectively prevents development of acute neonatal seizures in an animal model of global hypoxia. *Neurosci Lett* 2015; **607**: 46-51 [PMID: 26365409 DOI: 10.1016/j.neulet.2015.09.005]

37 **Sampath D**, Valdez R, White AM, Raol YH. Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy. *Neuropharmacology* 2017; **123**: 126-135 [PMID: 28587899 DOI: 10.1016/j.neuropharm.2017.06.002]

38 **Ben-Ari Y**. Excitatory actions of gaba during development: the nature of the nurture. *Nat Rev Neurosci* 2002; **3**: 728-739 [PMID: 12209121 DOI: 10.1038/nrn920]

39 **Brooks-Kayal AR**, Pritchett DB. Developmental changes in human gamma-aminobutyric acidA receptor subunit composition. *Ann Neurol* 1993; **34**: 687-693 [PMID: 7694542 DOI: 10.1002/ana.410340511]

40 **Phabphal K**, Chisurajinda S, Somboon T, Unwongse K, Geater A. Does burst-suppression achieve seizure control in refractory status epilepticus? *BMC Neurol* 2018; **18**: 46 [PMID: 29679985 DOI: 10.1186/s12883-018-1050-3]

41 **Zhang T**, Todorovic MS, Williamson J, Kapur J. Flupirtine and diazepam combination terminates established status epilepticus: results in three rodent models. *Ann Clin Transl Neurol* 2017; **4**: 888-896 [PMID: 29296617 DOI: 10.1002/acn3.497]

42 **Hauser WA**. The prevalence and incidence of convulsive disorders in children. *Epilepsia* 1994; **35** Suppl 2: S1-S6 [PMID: 8275976]

43 **Chang YC**, Huang AM, Kuo YM, Wang ST, Chang YY, Huang CC. Febrile seizures impair memory and cAMP response-element binding protein activation. *Ann Neurol* 2003; **54**: 706-718 [PMID: 14681880 DOI: 10.1002/ana.10789]

44 **Lux AL**. Treatment of febrile seizures: historical perspective, current opinions, and potential future directions. *Brain Dev* 2010; **32**: 42-50 [PMID: 19854599 DOI: 10.1016/j.braindev.2009.09.016]

45 **Yu F**, Liu Y, Wang Y, Yin J, Wang H, Liu W, Peng B, He X. Protective effect of the KCNQ activator flupirtine on a model of repetitive febrile seizures. *Epilepsy Res* 2011; **97**: 64-72 [PMID: 21831598 DOI: 10.1016/j.eplepsyres.2011.07.005]

46 **Safiulina VF**, Zacchi P, Taglialatela M, Yaari Y, Cherubini E. Low expression of Kv7/M channels facilitates intrinsic and network bursting in the developing rat hippocampus. *J Physiol* 2008; **586**: 5437-5453 [PMID: 18801845 DOI: 10.1113/jphysiol.2008.156257]

47 **Schuster G,** Schwarz M, Block F, Pergande G, Schmiddt WJ. Flupirtine: A review of its neuroprotective and behavioral properties. CNS Drug Rev 1998; 4: 149-164. [DOI: 10.1111/j.1527-3458.1998.tb00061.x]

48 **Dhar S**, Bitting RL, Rylova SN, Jansen PJ, Lockhart E, Koeberl DD, Amalfitano A, Boustany RM. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. *Ann Neurol* 2002; **51**: 448-466 [PMID: 11921051 DOI: 10.1002/ana.10143]

49 **Block F**, Pergande G, Schwarz M. Flupirtine reduces functional deficits and neuronal damage after global ischemia in rats. *Brain Res* 1997; **754**: 279-284 [PMID: 9134985]

50 **Rupalla K**, Cao W, Krieglstein J. Flupirtine protects neurons against excitotoxic or ischemic damage and inhibits the increase in cytosolic Ca2+ concentration. *Eur J Pharmacol* 1995; **294**: 469-473 [PMID: 8750707]

51 **Jaeger HM**, Pehlke JR, Kaltwasser B, Kilic E, Bähr M, Hermann DM, Doeppner TR. The indirect NMDAR inhibitor flupirtine induces sustained post-ischemic recovery, neuroprotection and angioneurogenesis. *Oncotarget* 2015; **6**: 14033-14044 [PMID: 26050199 DOI: 10.18632/oncotarget.4226]

52 **Rami A**, Krieglstein J. Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. *Brain Res* 1993; **609**: 67-70 [PMID: 8508322]

53 **Lucassen PJ**, Heine VM, Muller MB, van der Beek EM, Wiegant VM, De Kloet ER, Joels M, Fuchs E, Swaab DF, Czeh B. Stress, depression and hippocampal apoptosis. *CNS Neurol Disord Drug Targets* 2006; **5**: 531-546 [PMID: 17073656]

54 **Huang P**, Li C, Fu T, Zhao D, Yi Z, Lu Q, Guo L, Xu X. Flupirtine attenuates chronic restraint stress-induced cognitive deficits and hippocampal apoptosis in male mice. *Behav Brain Res* 2015; **288**: 1-10 [PMID: 25869780 DOI: 10.1016/j.bbr.2015.04.004]

55 **Li C**, Huang P, Lu Q, Zhou M, Guo L, Xu X. KCNQ/Kv7 channel activator flupirtine protects against acute stress-induced impairments of spatial memory retrieval and hippocampal LTP in rats. *Neuroscience* 2014; **280**: 19-30 [PMID: 25234320 DOI: 10.1016/j.neuroscience.2014.09.009]

56 **Ghavami S**, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, Christoffersson J, Chaabane W, Moghadam AR, Kashani HH, Hashemi M, Owji AA, Łos MJ. Autophagy and apoptosis dysfunction in neurodegenerative disorders. *Prog Neurobiol* 2014; **112**: 24-49 [PMID: 24211851 DOI: 10.1016/j.pneurobio.2013.10.004]

57 **Perovic S**, Schröder HC, Pergande G, Ushijima H, Müller WE. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). *Exp Neurol* 1997; **147**: 518-524 [PMID: 9344576 DOI: 10.1006/exnr.1997.6559]

58 **Otto M**, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, Irle E, Pergande G, Ellers-Lenz B, Windl O, Kretzschmar HA, Poser S, Prange H. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. *Neurology* 2004; **62**: 714-718 [PMID: 15007119]

59 **Schmidt WJ**, Schuster G, Wacker E, Pergande G. Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. *Eur J Pharmacol* 1997; **327**: 1-9 [PMID: 9185829 DOI: 10.1016/S0014-2999(97)89671-9]

60 **Schwarz M**, Nolden-Koch M, Purr J, Pergande G, Block F. Antiparkinsonian effect of flupirtine in monoamine-depleted rats. *J Neural Transm* (Vienna) 1996; **103**: 581-590 [PMID: 8811503 DOI: 10.1007/BF01273155]

61 **Su TR,** Zei WS, Su CC, Hsiao G, Lin MJ. The Effects of the KCNQ Openers Retigabine and Flupirtine on Myotonia in Mammalian Skeletal Muscle Induced by a Chloride Channel Blocker. *Evid Based Complement Alternat Med* 2012; **2012**: 803082 [PMID: 22536291 DOI: 10.1155/2012/803082]

62 **Glasscock E**, Qian J, Kole MJ, Noebels JL. Transcompartmental reversal of single fibre hyperexcitability in juxtaparanodal Kv1.1-deficient vagus nerve axons by activation of nodal KCNQ channels. *J Physiol* 2012; **590**: 3913-3926 [PMID: 22641786 DOI: 10.1113/jphysiol.2012.235606]

63 **Iannotti FA,** Panza E, Barrese V, Viggiano D, Soldovieri MV, Taglialatela M. Expression, localization, and pharmacological role of Kv7 potassium channels in skeletal muscle proliferation, differentiation, and survival after myotoxic insults. *J Pharmacol Exp Ther* 2010; 332: 811-820 [PMID: 20040580 DOI: 10.1124/jpet.109.162800]

64 **Kleopa KA**, Elman LB, Lang B, Vincent A, Scherer SS. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. *Brain* 2006; **129**: 1570-1584 [PMID: 16613892 DOI: 10.1093/brain/awl084]

65 **Tomlinson SE**, Tan SV, Kullmann DM, Griggs RC, Burke D, Hanna MG, Bostock H. Nerve excitability studies characterize Kv1.1 fast potassium channel dysfunction in patients with episodic ataxia type 1. *Brain* 2010; **133**: 3530-3540 [PMID: 21106501 DOI: 10.1093/brain/awq318]

66 **Stott JB,** Jepps TA, Greenwood IA. K(V)7 potassium channels: a new therapeutic target in smooth muscle disorders. *Drug Discov Today* 2014; **19**: 413-424 [PMID: 24333708 DOI: 10.1016/j.drudis.2013.12.003]

67 **Mackie AR**, Byron KL. Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention. *Mol Pharmacol* 2008; **74**: 1171-1179 [PMID: 18684841 DOI: 10.1124/mol.108.049825]

68 **Goodwill AG**, Fu L, Noblet JN, Casalini ED, Sassoon D, Berwick ZC, Kassab GS, Tune JD, Dick GM. KV7 channels contribute to paracrine, but not metabolic or ischemic, regulation of coronary vascular reactivity in swine. *Am J Physiol Heart Circ Physiol* 2016; **310**: H693-H704 [PMID: 26825518 DOI: 10.1152/ajpheart.00688.2015]

69 **Liu Y**, Terata K, Rusch NJ, Gutterman DD. High glucose impairs voltage-gated K(+) channel current in rat small coronary arteries. *Circ Res* 2001; **89**: 146-152 [PMID: 11463721]

70 **Heaps CL**, Tharp DL, Bowles DK. Hypercholesterolemia abolishes voltage-dependent K+ channel contribution to adenosine-mediated relaxation in porcine coronary arterioles. *Am J Physiol Heart Circ Physiol* 2005; **288**: H568-H576 [PMID: 15458946]

71 **Hyvelin JM**, Gautier M, Lemaire MC, Bonnet P, Eder V. Adaptative modifications of right coronary myocytes voltage-gated K+ currents in rat with hypoxic pulmonary hypertension. *Pflugers Arch* 2009; **457**: 721-730 [PMID: 18633640 DOI: 10.1007/s00424-008-0546-x]

72 **Jepps TA**, Chadha PS, Davis AJ, Harhun MI, Cockerill GW, Olesen SP, Hansen RS, Greenwood IA. Downregulation of Kv7.4 channel activity in primary and secondary hypertension. *Circulation* 2011; **124**: 602-611 [PMID: 21747056 DOI: 10.1161/CIRCULATIONAHA.111.032136]

73 **Morales-Cano D**, Moreno L, Barreira B, Pandolfi R, Chamorro V, Jimenez R, Villamor E, Duarte J, Perez-Vizcaino F, Cogolludo A. Kv7 channels critically determine coronary artery reactivity: left-right differences and down-regulation by hyperglycaemia. *Cardiovasc Res* 2015; **106**: 98-108 [PMID: 25616413 DOI: 10.1093/cvr/cvv020]

74 **Khanamiri S**, Soltysinska E, Jepps TA, Bentzen BH, Chadha PS, Schmitt N, Greenwood IA, Olesen SP. Contribution of Kv7 channels to basal coronary flow and active response to ischemia. *Hypertension* 2013; **62**: 1090-1097 [PMID: 24082059 DOI: 10.1161/HYPERTENSIONAHA.113.01244]

75 **Chen X**, Li W, Hiett SC, Obukhov AG. Novel Roles for Kv7 Channels in Shaping Histamine-Induced Contractions and Bradykinin-Dependent Relaxations in Pig Coronary Arteries. *PLoS One* 2016; **11**: e0148569 [PMID: 26844882 DOI: 10.1371/journal.pone.0148569]

76 **Sedivy V**, Joshi S, Ghaly Y, Mizera R, Zaloudikova M, Brennan S, Novotna J, Herget J, Gurney AM. Role of Kv7 channels in responses of the pulmonary circulation to hypoxia. *Am J Physiol Lung Cell Mol Physiol* 2015; **308**: L48-L57 [PMID: 25361569 DOI: 10.1152/ajplung.00362.2013]

77 **Morecroft I**, Murray A, Nilsen M, Gurney AM, MacLean MR. Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. *Br J Pharmacol* 2009; **157**: 1241-1249 [PMID: 19508393 DOI: 10.1111/j.1476-5381.2009.00283.x]

78 **Anderson UA**, Carson C, Johnston L, Joshi S, Gurney AM, McCloskey KD. Functional expression of KCNQ (Kv7) channels in guinea pig bladder smooth muscle and their contribution to spontaneous activity. *Br J Pharmacol* 2013; **169**: 1290-1304 [PMID: 23586426 DOI: 10.1111/bph.12210]

79 **Takagi H**, Hashitani H. Effects of K(+) channel openers on spontaneous action potentials in detrusor smooth muscle of the guinea-pig urinary bladder. *Eur J Pharmacol* 2016; **789**: 179-186 [PMID: 27455901 DOI: 10.1016/j.ejphar.2016.07.041]

80 **Lee K**, Isogai A, Antoh M, Kajioka S, Eto M, Hashitani H. Role of K+ channels in regulating spontaneous activity in the muscularis mucosae of guinea pig bladder. *Eur J Pharmacol* 2018; **818**: 30-37 [PMID: 29050967 DOI: 10.1016/j.ejphar.2017.10.024]

81 **Bientinesi R**, Mancuso C, Martire M, Bassi PF, Sacco E, Currò D. KV7 channels in the human detrusor: channel modulator effects and gene and protein expression. *Naunyn Schmiedebergs Arch Pharmacol* 2017; **390**: 127-137 [PMID: 27761601 DOI: 10.1007/s00210-016-1312-9]

82 **Svalø J**, Hansen HH, Rønn LC, Sheykhzade M, Munro G, Rode F. Kv 7 positive modulators reduce detrusor overactivity and increase bladder capacity in rats. *Basic Clin Pharmacol Toxicol* 2012; **110**: 145-153 [PMID: 21895977 DOI: 10.1111/j.1742-7843.2011]

83 **Vahabi B**, Drake MJ. Physiological and pathophysiological implications of micromotion activity in urinary bladder function. *Acta Physiol* (Oxf) 2015; **213**: 360-370 [PMID: 25154454 DOI: 10.1111/apha.12373]

84 **McCallum LA**, Pierce SL, England SK, Greenwood IA, Tribe RM. The contribution of Kv7 channels to pregnant mouse and human myometrial contractility. *J Cell Mol Med* 2011; **15**: 577-586 [PMID: 20132415 DOI: 10.1111/j.1582-4934.2010.01021.x]

**85** Summary of product characteristics. Flupirtine maleate. 2015. Available from: URL: http://mri.cts-mrp.eu/download/DE\_H\_3430\_001\_FinalSPC\_2of2.pdf

86 **Ipavec V**, Martire M, Barrese V, Taglialatela M, Currò D. KV7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus. *Pharmacol Res* 2011; **64**: 397-409 [PMID: 21740972 DOI: 10.1016/j.phrs.2011.06.016]

87 **Adduci A**, Martire M, Taglialatela M, Arena V, Rizzo G, Coco C, Currò D. Expression and motor functional roles of voltage-dependent type 7 K(+) channels in the human taenia coli. *Eur J Pharmacol* 2013; **721**: 12-20 [PMID: 24120659 DOI: 10.1016/j.ejphar.2013.09.061]

88 **Currò D**. K+ channels as potential targets for the treatment of gastrointestinal motor disorders. *Eur J Pharmacol* 2014; **733**: 97-101 [PMID: 24726846 DOI: 10.1016/j.ejphar.2014.03.049]

89 **Brueggemann LI**, Kakad PP, Love RB, Solway J, Dowell ML, Cribbs LL, Byron KL. Kv7 potassium channels in airway smooth muscle cells: signal transduction intermediates and pharmacological targets for bronchodilator therapy. *Am J Physiol Lung Cell Mol Physiol* 2012; **302**: L120-L132 [PMID: 21964407 DOI: 10.1152/ajplung.00194.2011]

90 **Brueggemann LI,** Mackie AR, Martin JL, Cribbs LL, Byron KL. Diclofenac distinguishes among homomeric and heteromeric potassium channels composed of KCNQ4 and KCNQ5 subunits. *Mol Pharmacol* 2011; **79**: 10-23 [PMID: 20876743 DOI: 10.1124/mol.110.067496]

91 **Evseev AI**, Semenov I, Archer CR, Medina JL, Dube PH, Shapiro MS, Brenner R. Functional effects of KCNQ K(+) channels in airway smooth muscle. *Front Physiol* 2013; **4**: 277 [PMID: 24109455 DOI: 10.3389/fphys.2013.00277]

92 **Li S**, Choi V, Tzounopoulos T. Pathogenic plasticity of Kv7.2/3 channel activity is essential for the induction of tinnitus. *Proc Natl Acad Sci USA* 2013; **110**: 9980-9985 [PMID: 23716673 DOI: 10.1073/pnas.1302770110]

93 **Wu C**, V Gopal K, Lukas TJ, Gross GW, Moore EJ. Pharmacodynamics of potassium channel openers in cultured neuronal networks. *Eur J Pharmacol* 2014; **732**: 68-75 [PMID: 24681057 DOI: 10.1016/j.ejphar.2014.03.017]

94 **Choi H**, Zhang L, Cembrowski MS, Sabottke CF, Markowitz AL, Butts DA, Kath WL, Singer JH, Riecke H. Intrinsic bursting of AII amacrine cells underlies oscillations in the rd1 mouse retina. *J Neurophysiol* 2014; **112**: 1491-1504 [PMID: 25008417 DOI: 10.1152/jn.00437.2014]

95 **Barrett JM**, Degenaar P, Sernagor E. Blockade of pathological retinal ganglion cell hyperactivity improves optogenetically evoked light responses in rd1 mice. *Front Cell Neurosci* 2015; **9**: 330 [PMID: 26379501 DOI: 10.3389/fncel.2015.00330]

96 **Tu HY**, Chen YJ, McQuiston AR, Chiao CC, Chen CK. A Novel Retinal Oscillation Mechanism in an Autosomal Dominant Photoreceptor Degeneration Mouse Model. *Front Cell Neurosci* 2016; **9**: 513 [PMID: 26793064 DOI: 10.3389/fncel.2015.00513]

97 **Puls F**, Agne C, Klein F, Koch M, Rifai K, Manns MP, Borlak J, Kreipe HH. Pathology of flupirtine-induced liver injury: a histological and clinical study of six cases. *Virchows Arch* 2011; **458**: 709-716 [PMID: 21590308 DOI: 10.1007/s00428-011-1087-9]

98 **Anderson N**, Borlak J. Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting. *PLoS One* 2011; **6**: e25221 [PMID: 22022383 DOI: 10.1371/journal.pone.0025221]

99 **Methling K**, Reszka P, Lalk M, Vrana O, Scheuch E, Siegmund W, Terhaag B, Bednarski PJ. Investigation of the in vitro metabolism of the analgesic flupirtine. *Drug Metab Dispos* 2009; **37**: 479-493 [PMID: 19074524 DOI: 10.1124/dmd.108.024364]

100 **Konishi K**, Fukami T, Ogiso T, Nakajima M. In vitro approach to elucidate the relevance of carboxylesterase 2 and N-acetyltransferase 2 to flupirtine-induced liver injury. *Biochem Pharmacol* 2018; **155**: 242-251 [PMID: 30028988 DOI: 10.1016/j.bcp.2018.07.019]

101 **Boelsterli UA**. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. *Toxicol Appl Pharmacol* 2003; **192**: 307-322 [PMID: 14575648]

102 **Park BK**, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of metabolic activation in drug-induced hepatotoxicity. *Annu Rev Pharmacol Toxicol* 2005; **45**: 177-202 [PMID: 15822174]

103 **Cascorbi I**, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. *Am J Hum Genet* 1995; **57**: 581-592 [PMID: 7668286]

104 **Nicoletti P**, Werk AN, Sawle A, Shen Y, Urban TJ, Coulthard SA, Bjornsson ES, Cascorbi I, Floratos A, Stammschulte T, Gundert-Remy U, Nelson MR, Aithal GP, Daly AK; International Drug-induced Liver Injury Consortium. HLA-DRB1\*16: 01-DQB1\*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. *Pharmacogenet Genomics* 2016; **26**: 218-224 [PMID: 26959717 DOI: 10.1097/FPC.0000000000000209]

105 **Borlak J**, van Bömmel F, Berg T. N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury. *Liver Int* 2018; **38**: 365-376 [PMID: 28782153 DOI: 10.1111/liv.13538]

106 European Medicines Agency. Restrictions in the use of flupirtine-containing medicines. 2013 [Cited 14 November 2018] Available from: URL: https://www.ema.europa.eu/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing\_en-0.pdf

107 European Medicines Agency. Withdrawal of pain medicine flupirtine endorsed. 2018 [Cited 14 November 2018] Available from: URL: https://www.ema.europa.eu/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed\_en.pdf

108 **Kaplan S**, Ehlken B, Hamann X. The impact of risk minimization measures on compliance and prescribing practices of flupirtine in Germany. *Curr Med Res Opin* 2018; 1-8 [PMID: 29992843 DOI: 10.1080/03007995.2018.1499507]

109 **Lemmerhirt CJ**, Rombach M, Bodtke A, Bednarski PJ, Link A. Oxidation potentials of N-modified derivatives of the analgesic flupirtine linked to potassium KV 7 channel opening activity but not hepatocyte toxicity. *ChemMedChem* 2015; **10**: 368-379 [PMID: 25392984 DOI: 10.1002/cmdc.201402442]

**P-Reviewer:** Burk J, Currò D **S-Editor:** Cui LJ **L-Editor: E-Editor:**

**Specialty type:** Pharmacology and pharmacy

**Country of origin:** United Kingdom

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Summary of pharmacological profile and potential clinical applications of flupirtine**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Molecular target** | **Clinical condition** | **References** |
| Analgesia | Kv7.2, Kv7.3, Kv7.5 channels  GIRK channels  GABAA receptors | Persistent pain  Acute pain | [2,16,24,27] |
| Anticonvulsant | Kv7.2, Kv7.3, Kv7.5 channels  GIRK channels | Neonatal seizures  Repetitive febrile seizures | [33-35,38-39, 43] |
| Neuroprotection | Kv7 channels - indirect NMDA receptor antagonism  Bcl-2 protein  Glutathione | Stroke  Chronic stress  Prion diseases  Parkinson's disease  Alzheimer's disease | [47-49,52,53, 55,56] |
| Skeletal muscle relaxant | Kv7.2, Kv7.3, Kv7.4 channels | Spinal Polysynaptic reflexes  Myotonia  Parkinson's disease | [60-63] |
| Vascular smooth muscle relaxation | Kv7.4, Kv7.5 channels  Unidentified mechanism | Coronary artery disease, angina  Pulmonary hypertension | [69,74-76] |
| Urinary bladder smooth muscle relaxation | Kv7.4 channels | Overactive bladder  Detrusor overactivity | [78-80] |
| Myometrial smooth muscle relaxation | Kv7 channels | Preterm labour (tocolysis) | [83] |
| Gastrointestinal smooth muscle relaxation | Kv7.4, Kv7.5 channels | Functional dyspepsia  Irritable bowel syndrome | [84-86] |
| Respiratory smooth muscle relaxation | Kv7.4, Kv7.5 channels | Asthma | [88,89] |
| Auditory stabilization | Kv7.2, Kv7.3 channels | Tinnitus | [91] |
| Retinal stabilization | Kv7 channels | Photoreceptor dystrophic disorders  Age related macular degeneration  Blindness | [92-94] |
| Memory formation | Kv7 channels | Learning and memory impairment  Cognitive processing | [52,53] |

GIRK: G-protein-regulated inwardly rectifying K+ channels; GABA: γ-aminobutyric acid; NMDA: N-methyl-D-aspartate.